| Dr Chantal Josee Boisvert, OD, MD | |
|
111 Colchester Ave, Burlington, VT 05401-1473 | |
| (802) 847-0400 | |
| Not Available |
| Full Name | Dr Chantal Josee Boisvert |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 21 Years |
| Location | 111 Colchester Ave, Burlington, Vermont |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366606055 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Univ. Of Vermont - Fletcher Allen Health Care | Burlington, VT | Hospital |
| Rutland Regional Medical Center | Rutland, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Vermont Medical Center Inc | 3779491071 | 994 |
News Archive
TessArae, LLC, a privately held company, and Affymetrix Inc., (NASDAQ:AFFX) today announced that the Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to TessArae for its TessArray® Resequencing Influenza A Microarray Detection Panel for the Detection of the 2009 H1N1 Influenza A Virus (TessArray RM-Flu test) for the duration of the declaration of emergency unless revoked earlier. The declaration of emergency will expire on April 26, 2010, unless terminated earlier or renewed.
A recent poll of healthcare providers indicates that as the country moves through healthcare reform and defining "meaningful use," providers plan to make better use of healthcare information technology when it comes to their everyday practices.
With nearly half of the world's population at risk for life-threatening malaria infections, University of Maryland School of Medicine (UMSOM) researchers and their colleagues identified an important public health measure to control the disease.
Cancer researchers are increasingly aware that in addition to genetic mutations in a cancer itself, characteristics of the surrounding tissue can promote or suppress tumor growth. One of these important tissue characteristics is inflammation - most cancers prosper in and attach to inflamed tissue and so many cancers have developed ways to create it.
In a large-scale, international study led by renowned rheumatologist Josef Smolen from the Department of Medicine III, a still-to-be-approved drug containing the selective janus kinase inhibitor upadacitinib has proved itself to be a new option for treating active rheumatoid arthritis.
› Verified 2 days ago
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
TessArae, LLC, a privately held company, and Affymetrix Inc., (NASDAQ:AFFX) today announced that the Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to TessArae for its TessArray® Resequencing Influenza A Microarray Detection Panel for the Detection of the 2009 H1N1 Influenza A Virus (TessArray RM-Flu test) for the duration of the declaration of emergency unless revoked earlier. The declaration of emergency will expire on April 26, 2010, unless terminated earlier or renewed.
A recent poll of healthcare providers indicates that as the country moves through healthcare reform and defining "meaningful use," providers plan to make better use of healthcare information technology when it comes to their everyday practices.
With nearly half of the world's population at risk for life-threatening malaria infections, University of Maryland School of Medicine (UMSOM) researchers and their colleagues identified an important public health measure to control the disease.
Cancer researchers are increasingly aware that in addition to genetic mutations in a cancer itself, characteristics of the surrounding tissue can promote or suppress tumor growth. One of these important tissue characteristics is inflammation - most cancers prosper in and attach to inflamed tissue and so many cancers have developed ways to create it.
In a large-scale, international study led by renowned rheumatologist Josef Smolen from the Department of Medicine III, a still-to-be-approved drug containing the selective janus kinase inhibitor upadacitinib has proved itself to be a new option for treating active rheumatoid arthritis.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Chantal Josee Boisvert, OD, MD 2351 Erwin Rd, Durham, NC 27705-4699 Ph: (919) 681-9191 | Dr Chantal Josee Boisvert, OD, MD 111 Colchester Ave, Burlington, VT 05401-1473 Ph: (802) 847-0400 |
News Archive
TessArae, LLC, a privately held company, and Affymetrix Inc., (NASDAQ:AFFX) today announced that the Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to TessArae for its TessArray® Resequencing Influenza A Microarray Detection Panel for the Detection of the 2009 H1N1 Influenza A Virus (TessArray RM-Flu test) for the duration of the declaration of emergency unless revoked earlier. The declaration of emergency will expire on April 26, 2010, unless terminated earlier or renewed.
A recent poll of healthcare providers indicates that as the country moves through healthcare reform and defining "meaningful use," providers plan to make better use of healthcare information technology when it comes to their everyday practices.
With nearly half of the world's population at risk for life-threatening malaria infections, University of Maryland School of Medicine (UMSOM) researchers and their colleagues identified an important public health measure to control the disease.
Cancer researchers are increasingly aware that in addition to genetic mutations in a cancer itself, characteristics of the surrounding tissue can promote or suppress tumor growth. One of these important tissue characteristics is inflammation - most cancers prosper in and attach to inflamed tissue and so many cancers have developed ways to create it.
In a large-scale, international study led by renowned rheumatologist Josef Smolen from the Department of Medicine III, a still-to-be-approved drug containing the selective janus kinase inhibitor upadacitinib has proved itself to be a new option for treating active rheumatoid arthritis.
› Verified 2 days ago
Dr. Jeffery Danny Young, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Elizabeth Houle, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Uvm Medical Center, Burlington, VT 05401 Phone: 802-847-1237 Fax: 802-847-5963 | |
Dr. Jonathan Daniel Paul, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-3843 Fax: 802-847-1481 | |
Dr. Robert Hugh Millay, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-4520 Fax: 802-847-8902 | |
Jessica J Mcnally, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave., Uvm Medical Center, Surgery/ophthalmology, Burlington, VT 05401 Phone: 802-847-8484 Fax: 802-847-9462 | |
Dr. Stephen Michael Pecsenyicki, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-3843 Fax: 802-847-1481 |